[HTML][HTML] Comprehensive physicochemical characterization of a peptide-based medicine: Teduglutide (Revestive®) structural description and stress testing
R Pérez-Robles, A Salmerón-García… - European Journal of …, 2023 - Elsevier
Teduglutide (Revestive®) is a glucagon-like peptide-2 analogue used for the treatment of
short bowel syndrome, a rare life-threatening condition in which the amount of functional gut …
short bowel syndrome, a rare life-threatening condition in which the amount of functional gut …
[HTML][HTML] Comprehensive Analysis of Cetuximab Critical Quality Attributes: Impact of Handling on Antigen-Antibody Binding
A Torres-García, A Torrente-López, J Hermosilla… - Pharmaceutics, 2024 - mdpi.com
Background/Objectives: Cetuximab, formulated in Erbitux®(5 mg/mL), is a therapeutic
monoclonal antibody (mAb) widely used in several cancer treatments. Currently, there is …
monoclonal antibody (mAb) widely used in several cancer treatments. Currently, there is …
Size‐exclusion LC‐UV/HRMS based method for the analysis of aggregates in synthetic GLP‐1 analog liraglutide and evaluation of excipient impact on aggregation
D Badgujar, S Bawake, A Chawathe… - Biomedical …, 2024 - Wiley Online Library
Peptide aggregation is one of the key challenges associated with the development of
therapeutic peptides. Peptide and protein aggregates are considered as one of the most …
therapeutic peptides. Peptide and protein aggregates are considered as one of the most …